Indaptus Therapeutics Statistics
Share Statistics
Indaptus Therapeutics has 12.01M shares outstanding. The number of shares has increased by 21.38% in one year.
| Shares Outstanding | 12.01M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 19.42% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 9.25M |
| Failed to Deliver (FTD) Shares | 144 |
| FTD / Avg. Volume | 0.13% |
Short Selling Information
The latest short interest is 138.70K, so 1.36% of the outstanding shares have been sold short.
| Short Interest | 138.70K |
| Short % of Shares Out | 1.36% |
| Short % of Float | 1.85% |
| Short Ratio (days to cover) | 0.54 |
Valuation Ratios
The PE ratio is -0.96 and the forward PE ratio is -0.83.
| PE Ratio | -0.96 |
| Forward PE | -0.83 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.22 |
| P/FCF Ratio | -1.1 |
| PEG Ratio | n/a |
Enterprise Valuation
Indaptus Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 5.05, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.05 |
| Quick Ratio | 5.05 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.84 |
| Cash Flow / Debt | -131.81 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.28% and return on capital (ROIC) is -133.68%.
| Return on Equity (ROE) | -1.28% |
| Return on Assets (ROA) | -1.03% |
| Return on Capital (ROIC) | -133.68% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.20M |
| Employee Count | 7 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -48.48% in the last 52 weeks. The beta is 1.13, so Indaptus Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.13 |
| 52-Week Price Change | -48.48% |
| 50-Day Moving Average | 1.19 |
| 200-Day Moving Average | 1.84 |
| Relative Strength Index (RSI) | 42.43 |
| Average Volume (20 Days) | 113.91K |
Income Statement
In the last 12 months, Indaptus Therapeutics had revenue of $0 and earned -$15.42M in profits. Earnings per share was $-1.84.
| Revenue | 0 |
| Gross Profit | -1.28K |
| Operating Income | -16.38M |
| Net Income | -15.42M |
| EBITDA | -16.38M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.84 |
Balance Sheet
The company has $13.36M in cash and $175.05K in debt, giving a net cash position of $13.19M.
| Cash & Cash Equivalents | 13.36M |
| Total Debt | 175.05K |
| Net Cash | 13.19M |
| Retained Earnings | -45.42M |
| Total Assets | 8.24M |
| Working Capital | 5.40M |
Cash Flow
In the last 12 months, operating cash flow was -$13.41M and capital expenditures $0, giving a free cash flow of -$13.41M.
| Operating Cash Flow | -13.41M |
| Capital Expenditures | 0 |
| Free Cash Flow | -13.41M |
| FCF Per Share | -1.6 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
INDP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -180.39% |
| FCF Yield | -109.39% |
Analyst Forecast
The average price target for INDP is $8.5, which is 733.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.5 |
| Price Target Difference | 733.3% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jul 27, 2021. It was a backward split with a ratio of 1:4.
| Last Split Date | Jul 27, 2021 |
| Split Type | backward |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | -11.68 |
| Piotroski F-Score | 2 |